Melatonin attenuates carbon tetrachloride-induced liver fibrosis via inhibition of necroptosis. 2015

Hyo-Sun Choi, and Jung-Woo Kang, and Sun-Mee Lee
School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, Korea.

We investigated the protective mechanisms of melatonin (MLT) associated with necroptosis signaling and damage-associated molecular patterns, which are mediated by the activation of pattern recognition receptors in liver fibrosis. Rats were given an intraperitoneal injection of carbon tetrachloride (CCl4) dissolved in olive oil (1:3, vol/vol) twice a week (0.5 mL/kg) for 8 weeks. During this period, MLT was administered orally at 2.5, 5, and 10 mg/kg once a day. Chronic CCl4 administration increased hepatic hydroxyproline content and hepatocellular damage. MLT attenuated these increases. The expression levels of transforming growth factor β1 and α-smooth muscle actin that were increased by chronic CCl4 exposure were attenuated by MLT. CCl4 significantly increased receptor-interacting protein 1 (RIP1) expression, the formation of the RIP1 and RIP3 necrosome complex, and the level of mixed lineage kinase domain-like protein in liver tissue, which were attenuated by MLT. MLT also attenuated CCl4-induced increases in serum high-mobility group box 1 (HMGB1) and interleukin 1α, as well as the interaction between HMGB1 receptors for advanced glycation end products (RAGE). The increases in toll-like receptor 4 expression, p38, c-Jun N-terminal kinases phosphorylation, and nuclear factor κB translocation were suppressed by MLT. MLT attenuated the overexpression of RAGE, increased level of early growth response protein 1, and increased messenger RNA level of macrophage inflammatory protein 2. Our findings suggest MLT may prevent liver fibrosis by inhibiting necroptosis-associated inflammatory signaling.

UI MeSH Term Description Entries
D007378 Interleukins Soluble factors which stimulate growth-related activities of leukocytes as well as other cell types. They enhance cell proliferation and differentiation, DNA synthesis, secretion of other biologically active molecules and responses to immune and inflammatory stimuli. Interleukin
D008103 Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. Cirrhosis, Liver,Fibrosis, Liver,Hepatic Cirrhosis,Liver Fibrosis,Cirrhosis, Hepatic
D008297 Male Males
D008550 Melatonin A biogenic amine that is found in animals and plants. In mammals, melatonin is produced by the PINEAL GLAND. Its secretion increases in darkness and decreases during exposure to light. Melatonin is implicated in the regulation of SLEEP, mood, and REPRODUCTION. Melatonin is also an effective antioxidant.
D009336 Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
D011971 Receptors, Immunologic Cell surface molecules on cells of the immune system that specifically bind surface molecules or messenger molecules and trigger changes in the behavior of cells. Although these receptors were first identified in the immune system, many have important functions elsewhere. Immunologic Receptors,Immunologic Receptor,Immunological Receptors,Receptor, Immunologic,Receptors, Immunological
D002251 Carbon Tetrachloride A solvent for oils, fats, lacquers, varnishes, rubber waxes, and resins, and a starting material in the manufacturing of organic compounds. Poisoning by inhalation, ingestion or skin absorption is possible and may be fatal. (Merck Index, 11th ed) Tetrachloromethane,Tetrachloride, Carbon
D000067596 Interleukin-33 A member of the INTERLEUKIN-1 protein family involved in the maturation of TH2 CELLS and the activation of MAST CELLS; BASOPHILS; EOSINOPHILS and NK CELLS. It is also produced by ENDOTHELIAL CELLS; EPITHELIAL CELLS and FIBROBLASTS; where it can function as an alarmin to modulate immune and inflammatory responses to tissue damage. IL-33,IL33,Interleukin 33
D000067759 Receptor for Advanced Glycation End Products A single-pass transmembrane CELL SURFACE RECEPTOR that binds ADVANCED GLYCATION END PRODUCTS to mediate cellular responses to both acute and chronic vascular inflammation in conditions such as ATHEROSCLEROSIS and DIABETES MELLITUS, TYPE 2. Advanced Glycation End Product Receptor,Advanced Glycation End Product Receptors,Receptor For Advanced Glycation End Product,Receptor for Advanced Glycation Endproduct,AGE Receptor,AGER Protein,Amphoterin Receptor,RAGE (Receptor for Advanced Glycation End Products),Receptor for Advanced Glycation End Products (RAGE),Receptor for Advanced Glycation Endproducts,Receptor, Amphoterin
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Hyo-Sun Choi, and Jung-Woo Kang, and Sun-Mee Lee
January 2021, Frontiers in pharmacology,
Hyo-Sun Choi, and Jung-Woo Kang, and Sun-Mee Lee
August 2010, Hepatology research : the official journal of the Japan Society of Hepatology,
Hyo-Sun Choi, and Jung-Woo Kang, and Sun-Mee Lee
August 2007, World journal of gastroenterology,
Hyo-Sun Choi, and Jung-Woo Kang, and Sun-Mee Lee
November 2023, Biology,
Hyo-Sun Choi, and Jung-Woo Kang, and Sun-Mee Lee
September 2009, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie,
Hyo-Sun Choi, and Jung-Woo Kang, and Sun-Mee Lee
October 2012, Medical science monitor : international medical journal of experimental and clinical research,
Hyo-Sun Choi, and Jung-Woo Kang, and Sun-Mee Lee
September 1997, Journal of hepatology,
Hyo-Sun Choi, and Jung-Woo Kang, and Sun-Mee Lee
April 2018, Current medical science,
Hyo-Sun Choi, and Jung-Woo Kang, and Sun-Mee Lee
September 2010, Journal of hepatology,
Hyo-Sun Choi, and Jung-Woo Kang, and Sun-Mee Lee
July 2014, Experimental and therapeutic medicine,
Copied contents to your clipboard!